- Submission of Manuscripts
- Abstracting & Indexing
- Editorial Information
- More ...
- Comments (0)
Free Trial Access Available!
For free online access to all articles, please register on our website. To access the articles, simply click on "Get access to full text" on any article you wish to view.
Readers of Statistical Communications in Infectious Diseases have free access to Statistical Communications in Infectious Diseases articles. To access the articles, simply click on "Get access to full text" on any article you wish to view.
You can enjoy access to a number of De Gruyter economics journals. To enjoy access, click here.
Aims and Scope
To serve as the primary vehicle for the communication and education of statistical thinking in infectious disease research and policy.
The infectious diseases community faces many difficult challenges. These include: (1) coping with continuing high-impact diseases such as HIV, malaria, TB, and flu; (2) dealing with infectious disease outbreaks such as Ebola, pandemic avian influenza, or SARS; and (3) preparing for the inevitable emergence of diseases that are unknown or are recognized but will reemerge in a more threatening form (e.g., antibiotic resistant (nightmare) bacteria or superbugs). Research in infectious diseases is also challenged by funding limitations, politics, and ethical dilemmas.
Increasingly complex data is also creating new challenges to the design and analysis of research studies. Enhanced statistical expertise is essential to address these challenges and to develop and evaluate medical and public health responses to potential outbreaks and epidemics.
Statistical Communications in Infectious Diseases (SCID) publishes significant research on the application of statistical ideas to problems arising from studies of infectious diseases. SCID takes a broad perspective on the role of statistics in infectious disease research including application, policy, education and theory. SCID fosters much-needed communication among statisticians on the best approaches to evolving complex infectious disease data, and is a venue for statisticians to enter a dialogue with other scientists and policy makers on the strengths and limitations of policies and methods for design, monitoring, analysis, and reporting of infectious disease research studies.
SCID goes beyond the application of statistical methods to data arising from infectious disease studies or new statistical strategies. SCID serves as a sounding board to discuss policy issues, e.g.,
• How heavily should the public invest in research or implementation of different prevention modalities?
• What is necessary to achieve control of epidemics (for example, do we require a vaccine to control the spread of HIV or what procedures are required to halt the spread of Ebola)?
• How can statisticians help with grass roots epidemic control efforts?
• How can we optimally evaluate the benefits vs. harms vs. costs of competing interventions?
• How can we best characterize the trade-offs between civil liberties and public safety?
• How should we adjust the traditionally required level of evidence to address areas of unmet medical need?
• How do we revise our traditional approaches to the design, monitoring, analyses, and reporting of infectious disease studies to improve medical practice and public health?
• Engage and raise the quality of the discussions of important issues in the public and scientific press
• Ensure that optimal scientific tools are utilized in infectious disease research
• Improve the training and practice of the next generation of professionals involved in infectious diseases research through educational articles
• Raise the profile of quantitative science in infectious disease research by demonstrating its value in decision-making and public health
- Type of Publication:
Instructions for Authors
MANUSCRIPT PREPARATION GUIDELINES
This document provides authors with details on policy, copyediting, formatting, and layout requirements pertaining to final manuscript submission to this journal. All manuscripts must have correct formatting to be considered for publication.
The manuscript submission and review process is handled through ScholarOne Manuscripts. All manuscripts should be submitted to http://mc.manuscriptcentral.com/dgscid.
Unpublished material: Submission of a manuscript implies that the work described is not copyrighted, published or submitted elsewhere, except in abstract form. The corresponding author should ensure that all authors approve the manuscript before its submission.
Copyright: Manuscripts are accepted on condition of transfer of copyright (for U.S. government employees: to the extent transferable) to Statistical Communications in Infectious Diseases. Once the manuscript is accepted, it may not be published elsewhere without the consent of the copyright holders.
The ScholarOne system has been designed to improve the scholarly publication process for authors. Among the many improvements we offer over traditional journals, the most significant is that we have dramatically shortened the period between the initial submission and the final publication of a peer-reviewed article. Much of this time savings is due to the innovative use of electronic publication. These innovations, however, require certain changes in the way authors need to prepare accepted manuscripts for electronic publication.
De Gruyter does provide a light copyedit of manuscripts for this journal, but authors remain responsible for being their own copyeditors.
All manuscripts must be written in clear and concise English. If you have reasons to doubt your proficiency with respect to spelling, grammar, etc. (e.g., because English is not your native language), then you may wish to employ—at your expense—the services of a professional language editor.
Please get in touch with the Language Editors directly to discuss details.
• Alexandra Griswold
Areas of expertise: public policy, political science, education, economics, social sciences, humanities, ethics
• Cyndy Brown
Areas of expertise: political science, social sciences, humanities, ethics
• Donna Reeder
Reeder Literary Services
Areas of expertise: political science, economics, mathematical economics, natural sciences, social sciences, technology, law, humanities, liberal arts, literary studies, health and medicine
• Dorothy Schepps
Areas of expertise: political science, emergency management, homeland security, community/land use planning, law, economics, cyber terrorism, and cyber security
• Jane Cotnoir
Areas of expertise: Local government management, international crime and terrorism, emergency/disaster management, humanities, social science
• Patience Kramer
Areas of expertise: Health and Medicine (CAM and drug policy and analysis), Economics and Business (with a focus on marketing)
• Steve Peter
Areas of expertise: LaTeX, Linguistics, economics, mathematics
CONTENT AND STRUCTURE
• Manuscripts should be submitted as Word, docx, rtf, or LaTex files
• If your manuscript contains special characters, equations, etc. please make sure to also supply a PDF version as a reference file. This will be used to ensure any formatting issues introduced during the submission process can be corrected accurately.
• Write your article in English
• Use the following document structure:
1. Introduction (titling this section is optional)
2. Subsequent sections which include tables, references to figures and figure captions.
3. Appendices (if any).
4. Explanation of symbols mentioned in the text.
5. References - Include a proper bibliography following the guidelines in the References section below.
6. Please supply figures in separate files, not embedded in the text. Please see the “Tables, Figures, and Graphs” section below for more detailed instructions regarding figure submission.
• Book reviews must start with the citation of the book at the top of the first page.
For authors working with LaTeX files, please see the related files and documentation at http://www.degruyter.com/staticfiles/pdfs/DeGruyter_LaTeX_template_package.zip, including a template for author use and instructions for working with the files.
• Only use Unicode fonts (e.g. Times New Roman, Arial)
• Set the font color to black for the majority of the text. De Gruyter encourages authors to take advantage of the ability to use color in the production of figures, maps, images, and graphs. However, you need to appreciate that this will cause some of your readers problems when they print the document on a black and white printer. For this reason, you are advised to avoid the use of colors in situations where their translation to black and white would render the material illegible or incomprehensible.
EMPHASIZED TEXT, TITLES, AND FOREIGN TERMS
• To indicate text you wish to emphasize, use italics rather than underlining. The use of color to emphasize text is discouraged.
• Foreign terms should be set in italics rather than underlined.
• Titles of books, movies, etc., should be set in italics rather than underlined.
The use of abbreviations and acronyms is permitted provided they are defined the first time they are used.
Headings (e.g., title of sections) should be distinguished from the main body text:
• Clearly indicate the heading hierarchy.
• Be consistent in whether or not you use headline case, or you capitalize the first word and leave the rest in lower-case.
• Footnotes must appear at the bottom of the page on which they are referenced rather than at the end of the paper.
• Excessively long footnotes are better handled in an appendix.
TABLES, FIGURES & GRAPHS
• General requirements: All illustrations must be of reproduction-ready quality and in EPS, TIF, or JPG format. They will be reduced in size to fit, whenever possible, the width of a single column. Lettering of all figures within the article should be uniform in style (preferably a sans serif typeface like Helvetica) and of sufficient size (ca. 8 pt.).Uppercase letters A, B, C, etc. should be used to identify parts of multi-part figures. Cite all figures in the text in numerical order. Indicate the approximate placement of each figure. Do not embed figures within the text body of the manuscript; submit figures in separate files. Only figures (graphs, line drawings, photographs, etc) should be labeled as ‘figures’, not tables or equations.
• Halftone figures (grayscale and color) should have a minimum resolution of 300 dpi and be of good contrast. Authors are welcome to submit color illustrations. We are pleased to offer both Print and Online publication of color figures free of charge.the services of a professional language editor.
• Line drawings must be of reproduction-ready quality. Please note that faint shading may be lost upon reproduction. When drawing bar graphs, use patterning instead of grey scales. Lettering of all figures should be uniform in style. A resolution of 1200 dpi is recommended.
• Figure legends: Provide a short descriptive title and a legend to make each figure self-explanatory on separate pages. Explain all symbols used in the figures. Remember to use the same abbreviations as in the text body.
• Permissions: It is the authors’ responsibility to obtain permission to reproduce original or modified material that has been previously published. Any permissions fees are the responsibility of the author(s).
• Offprints: The electronic files of typeset articles in Adobe Acrobat PDF format are provided free of charge; corresponding authors receive notification that their article has been published online. Paper offprints can be ordered in addition; an offprint order form will accompany the page proofs and should be completed and returned with the corrected proofs immediately.
• Please do not embed figures in the text. Instead, they should be referenced in the text and submitted in separate files.
• Number tables consecutively using Arabic numerals. Tables should appear in the document near where they are referenced in the text. Provide a short descriptive title, column headings, and (if necessary) footnotes to make each table self-explanatory. Refer to tables in the text as Table 1, 2, etc. Use Table 1, etc. in the table legends.
• Tables must not be displayed as images.
MATHEMATICS AND EQUATIONS
• Roman letters used in mathematical expressions as variables must be italicized. Roman letters used as part of multi-letter function names should not be italicized. Subscripts and superscripts must be a smaller font size than the main text.
• Type short mathematical expressions inline.
• Longer expressions must appear as display math, as must expressions using many different levels (e.g., such as fractions).
• Ensure that Equations are typed or created with a plug-in, such as Word Formula Editor or MathType. Mathematical expressions must not be displayed as images
• Important definitions or concepts can also be set off as display math.
• Number your equations sequentially.
• Insert a blank line before and after each equation.
• Whether equation numbers are on the right or left is the choice of the author(s). However, make sure to be consistent in this.
• When proofing your document, pay particular attention to the rendering of the mathematics, especially symbols and notation drawn from other-than-standard fonts.
Please use the Chicago Manual of Style author-date system for parenthetical citation in the text and the related reference list entry. For more specific details please visit: http://www.chicagomanualofstyle.org/tools_citationguide.html and click on the Author-Date tab.
Statistical Communications in Infectious Diseases is covered by the following services:
- Baidu Scholar
- CABI (over 50 subsections)
- CNKI Scholar (China National Knowledge Infrastructure)
- Current Index to Statistics
- EBSCO (relevant databases)
- EBSCO Discovery Service
- Genamics JournalSeek
- Google Scholar
- Mathematical Reviews (MathSciNet)
- Naviga (Softweco)
- Primo Central (ExLibris)
- ProQuest (relevant databases)
- Summon (Serials Solutions/ProQuest)
- TDOne (TDNet)
- Ulrich's Periodicals Directory/ulrichsweb
- WorldCat (OCLC)
- Zentralblatt Math (zbMATH)
• Scott R. Evans, Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard University, USA
• Alfred Balch, University of Utah
• Brad J. Biggerstaff, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, USA
• Ron Bosch, Harvard T.H.Chan School of Public Health
• Ivan S.F. Chan, Clinical Biostatistics, Merck Research Laboratories, USA
• Xiao Ding, Biostatistics, Gilead Sciences, Inc., USA
• Marion Ewell, The Emmes Corporation, USA
• Dean Follmann, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
• Michael Hughes, Harvard T.H.Chan School of Public Health
• Lingling Li, Harvard Pilgrim Health Care Institute and Harvard Medical School, USA
• Honghu Liu, University of California Los Angeles
• Judith Lok, Harvard T.H.Chan School of Public Health
• Rhoderick Neri Machekano, Stellenbosch University, South Africa
• Farzad Noubary, Tufts University School of Medicine
• Dionne L. Price, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA
• Cavan Reilly, Division of Biostatistics, School of Public Health, University of Minnesota, USA
• Barbra Richardson, Department of Biostatistics, University of Washington, USA
• Dan Rubin, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA
• Pamela Shaw, Department of Biostatistics and Epidemiology, University of Pennsylvania, USA
• Norma Terrin, Tufts University School of Medicine
• Lu Tian, Department of Health Research and Policy, Stanford University, USA
• Kohei Uemura, Pharmaceutical and Medical Devices Agency, Japan
• Handan Wand, University of New South Wales, The Kirby Institute, Australia
• Rui Wang, Brigham and Women's Hospital and Harvard University, USA
• L.J. Wei, Harvard T.H.Chan School of Public Health
• Hulin Wu, University of Texas Health Science Center at Houston USA
• Henry F. Chambers, Division of Infectious Diseases, University of California San Francisco, USA
• Anthony Harris, University of Maryland School of Medicine, USA
• Norberto Pantoja-Galicia, Office of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, USA
• Gene Pennello, Office of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, USA